Medtronic has announced that it will highlight clinical and preclinical research relating to sensing-enabled spinal cord stimulation (SCS) therapy at the North American Neuromodulation Society (NANS) annual meeting (12–15 January 2023, Las Vegas, USA).
In addition, Medtronic and its partners will present new research on SCS for diabetic peripheral neuropathy (DPN), differential targeted multiplexed (DTM) SCS endurance therapy, and digital health.
SCS sensing technologies rely on evoked compound action potentials (ECAPs), or signals generated by the spinal cord in response to electrical stimulation.
Poster and oral scientific data presentations at NANS will highlight early clinical data and patient experience of sensing-enabled stimulation technologies, as well as targeted drug delivery solutions.
These poster and oral scientific data presentations reflect evidence from Medtronic-sponsored research and collaborations with external partners, according to a press release.
Poster presentations will be available to all NANS 2023 attendees, with an option to query the presenters throughout the conference, the release adds. A full list of Medtronic-sponsored presentations set to be delivered at the event can be found here.
